Study of OB-002 in Patients With Refractory Metastatic Cancer
Phase 1
Withdrawn
- Conditions
- Metastatic CancerMetastatic Urothelial CarcinomaMetastatic Colorectal CancerMetastatic Pancreatic CancerMetastatic Gastric CancerMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Orion Biotechnology Polska Sp. z o.o.
- Target Recruit Count
- 36
- Registration Number
- NCT05940844
OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Orion Biotechnology Polska Sp. z o.o.
- Target Recruit Count
- 60
- Registration Number
- NCT04791007
- Locations
- 🇵🇱
BioVirtus Centrum Medyczne Sp. z o.o., Józefów, Poland
© Copyright 2025. All Rights Reserved by MedPath